AstraZeneca to Evaluate Compendia's Oncomine Software

Dec 04, 2007

NEW YORK (GenomeWeb News) - AstraZeneca has licensed Compendia Bioscience’s data mining and visualization software, Compendia said today.

AstraZeneca will use the company’s Oncomine Concepts Edition software in a year-long pilot program in order to evaluate how it can be used in its cancer research programs.

Oncomine combines almost 7,000 proprietary cancer gene signatures with 11,000 gene, drug, and pathway signatures taken from the literature and other public sources, Compendia said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

An RNAi Approval

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Keep It Going

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Stop It There

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

This Week in PLOS

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Main menu